Porta-Vilaró Marta, Soler-Perromat Juan Carlos, Larque Ana-Belen, Bartolomé-Solanas Álvaro, Isern-Kebschull Jaime, García-Diez Ana-Isabel, Del Amo Montserrat, Fuster David, Momblan Dulce, Elizalde Jose Ignacio, Sauri Tamara, Tomás Xavier
Department of Radiology, Hospital Clínic de Barcelona, University of Barcelona (UB), Barcelona, Spain.
Department of Pathology, Hospital Clínic de Barcelona, University of Barcelona (UB), Barcelona, Spain.
Quant Imaging Med Surg. 2024 Nov 1;14(11):7872-7880. doi: 10.21037/qims-24-425. Epub 2024 Oct 14.
Gastric cancer (GC) is the fifth most common cancer globally and the third leading cause of cancer-related deaths. While it predominantly metastasizes to the liver, peritoneum, and lungs, bone metastasis (BM) is a rare but severe complication. BM occurs in 1-20% of GC cases and is associated with a poor prognosis. Typically, BM in GC presents at advanced stages, often with non-specific symptoms, making early detection challenging.
This retrospective study analyzed 118 GC patients treated at our institution from 2010 to 2020. Among them, eight patients (6.8%) developed BM, with an equal split between osteoblastic and osteolytic types. Osteoblastic BM was observed exclusively in men, with a mean age of 72.25 years. The median time from GC diagnosis to BM onset was 27.5 months. BM was primarily detected through periodic thoracoabdominal CT scans, and bone scintigraphy confirmed the osteoblastic nature of the lesions. All patients had advanced GC and were under palliative care at the time of BM diagnosis. The average survival time from BM diagnosis was 8.5 months.
BM in GC patients is rare but significantly worsens the prognosis. The findings suggest that osteoblastic BM may be more common in GC than previously reported, potentially due to improved imaging techniques and extended patient survival. This study underscores the importance of vigilant radiological monitoring in GC patients, particularly those with non-specific symptoms suggestive of BM. Enhanced collaboration between oncology and palliative care teams is essential to manage symptoms effectively and improve patient quality of life. Future research should focus on the incidence and management of BM in GC, particularly the role of targeted therapies in improving patient quality of life.
Bone metastasis (BM); gastric cancer (GC); osteoblastic; disease progression; case report.
胃癌(GC)是全球第五大常见癌症,也是癌症相关死亡的第三大主要原因。虽然它主要转移至肝脏、腹膜和肺部,但骨转移(BM)是一种罕见但严重的并发症。BM发生于1%至20%的GC病例中,且与预后不良相关。通常,GC中的BM在晚期出现,常伴有非特异性症状,这使得早期检测具有挑战性。
这项回顾性研究分析了2010年至2020年在我们机构接受治疗的118例GC患者。其中,8例患者(6.8%)发生了BM,成骨型和溶骨型各占一半。成骨型BM仅在男性中观察到,平均年龄为72.25岁。从GC诊断到BM发病的中位时间为27.5个月。BM主要通过定期的胸腹部CT扫描检测到,骨闪烁显像证实了病变的成骨性质。所有患者均患有晚期GC,在BM诊断时均接受姑息治疗。从BM诊断起的平均生存时间为8.5个月。
GC患者中的BM罕见,但会显著恶化预后。研究结果表明,GC中的成骨型BM可能比先前报道的更为常见,这可能是由于成像技术的改进和患者生存期的延长。本研究强调了对GC患者进行警惕的放射学监测的重要性,特别是那些有提示BM的非特异性症状的患者。肿瘤学和姑息治疗团队之间加强合作对于有效管理症状和提高患者生活质量至关重要。未来的研究应聚焦于GC中BM的发病率和管理,特别是靶向治疗在改善患者生活质量方面的作用。
骨转移(BM);胃癌(GC);成骨型;疾病进展;病例报告。